Live Breaking News & Updates on Royalty Linked Notes

Stay updated with breaking news from Royalty linked notes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Resubmission of NDA On Track for Early Q2 24— Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24 Company to host conference call today at 8:30amET DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today r ....

United States , Judy Matthews , Corey Fishman , Drug Administration , Recourse Royalty , Cash Runway , Chief Executive , Special Protocol Assessment , Resistant Enterobacterales , Complete Response Letter , Financial Advisor , Full Year , Prescription Drug User Fee Act , Exchangeable Senior Subordinated Notes , Iterum Therapeutics , Qualified Infectious Disease Product , Fast Track , Exchangeable Notes , Royalty Linked Notes , Maturity Date , Private Securities Litigation Reform Act , Nasdaq Capital Market , Annual Report , Financial Officer , Consolidated Statement ,